Onset
Not established; no human outcome data exists.
Protocol / Research Dosing Guide
AHK-Cu Dosage Guide: Topical Concentrations, Evidence and Safety
An evidence-organized AHK-Cu guide covering how the copper tripeptide is actually used — as a reconstituted topical serum measured in concentration, not as injected milligrams — and where the published evidence stops.
Last reviewed September 16, 202615 minute readResearch information only
Level 2 — Cell and ex-vivo evidenceNo published human trialsNot FDA approved
AHK-Cu Quick Start
AHK-Cu is a copper-binding tripeptide (alanine-histidine-lysine complexed with copper II), closely related to GHK-Cu. Because it is prepared as a serum and applied to the scalp or skin, the practical variable is concentration and application frequency rather than an injected amount. The most-cited work (Pyo et al., 2007) tested AHK-Cu on isolated human hair follicles and dermal papilla cells at picomolar-to-nanomolar concentrations in culture — not on people. No human trial, animal dosing study, or pharmacokinetic study of AHK-Cu was identified.
Why researchers care
Hair follicle, dermal papilla and skin research
Class
Copper tripeptide, Ala-His-Lys-Cu (GHK-Cu analogue)
Route reported
Community use is topical: powder dissolved into a scalp or skin serum
Cycle length
Not established
Regulatory status
Not FDA approved; research-use and cosmetic-ingredient contexts only
Loading supplier information
AHK-Cu Dosing Protocol and Schedule
No source establishes a validated human concentration or schedule. Self-reported community formulations describe roughly 1–2 mg/mL (about 0.1–0.2%) serums applied once or twice daily, a convention largely borrowed from how GHK-Cu cosmetic serums are mixed. Those figures are reported here as documented community practice, not as instructions. Every field without direct evidence is marked not established.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Validated human concentration | Not established | No controlled human trial has tested a topical strength |
| Community-reported serum strength | ~1–2 mg/mL (~0.1–0.2%) | Self-reported DIY formulations, not clinical dose-finding |
| Community-reported frequency | Once or twice daily to the scalp or skin | Descriptive of community practice only |
| Cell-culture concentrations | Picomolar to nanomolar (Pyo 2007) | Laboratory concentrations do not convert to a formulation percentage |
| Cycle or rest interval | Not established | No study defines one |
Cell-culture concentrations cannot be read across into a topical percentage, and community serum strengths are formulation habit rather than tested doses. No validated schedule, cycle, or rest period exists for AHK-Cu.
AHK-Cu Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured carrier volume for the serum
Research planning item
Clean mixing and storage container
Research planning item
Accurate volume measurement
Research planning item
Written concentration label
Research planning item
Refrigerated storage for the finished serum
AHK-Cu Reconstitution Calculator
Vial-format concentration math
Concentration
2 mg/mL
Draw volume
1 mL
U-100 units
100
Mathematical draws
25
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take AHK-Cu: Morning or Night?
Morning or evening?
Not established. Community sources describe daily application without a tested time of day.
Daily or intermittent?
Community reports describe once or twice daily; no study validates any cadence.
With microneedling?
Some community routines pair the serum with microneedling. That rationale comes from microneedling studies of other compounds, not from AHK-Cu trials.
Missed application?
No validated replacement procedure exists.
AHK-Cu Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Topical serum | The common community route: powder dissolved into a carrier and applied to scalp or skin | No controlled human trial of any topical strength |
| Topical + microneedling | Used as a penetration aid in some community routines | Microneedling evidence is for other compounds, not AHK-Cu |
| Subcutaneous injection | No community injection protocol for AHK-Cu was identified | No human safety or pharmacokinetic study |
| Oral | Not established | No exposure data |
| Route conversion | None available | Cell-culture concentrations and topical percentages are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
AHK-Cu Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human PK study |
| Animal half-life | Not established | No animal PK study identified |
| Skin penetration | Not established for AHK-Cu | The skin barrier limits peptide delivery; AHK-Cu-specific absorption has not been measured |
| Frequency | Not established | No studied regimen |
AHK-Cu Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Topical serum (community-reported) | ~1–2 mg/mL (~0.1–0.2%) | Once or twice daily | Self-reported community formulation | No |
| Cell culture (Pyo 2007) | Picomolar to nanomolar | — | In-vitro and ex-vivo follicle research | No |
| Any injected human amount | Not established | — | No human study | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
AHK-Cu Reconstitution Guide
Concentration: 1 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 2 mg | 2 mL | 200 units |
| 4 mg | 4 mL | 400 units |
| 6 mg | 6 mL | 600 units |
- 1.Confirm the exact vial label and total quantity in milligrams.
- 2.Decide the carrier volume that produces the concentration you want to record.
- 3.Clean the vial stopper and any mixing container.
- 4.Add the carrier slowly and swirl gently; do not shake.
- 5.Inspect for cloudiness, discoloration, or particles.
- 6.Label the calculated concentration and the preparation date.
- 7.Keep the finished serum refrigerated and protected from light; copper-peptide solutions are oxidation-sensitive.
- 8.Mix small batches; use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How AHK-Cu Works
Copper tripeptide family
AHK-Cu is an analogue of GHK-Cu, carrying copper into cell-culture systems.
AHK-Cu Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved; research-use and cosmetic-ingredient contexts only
- No published human trial of AHK-Cu was identified.
- No published animal dosing study of AHK-Cu was identified.
- The most-cited work is a 2007 in-vitro and ex-vivo study of human hair follicles and dermal papilla cells.
- A 2025 study of copper-peptide microneedling for androgenetic alopecia reported measurable regrowth, but did not test AHK-Cu as a standalone topical.
- AHK-Cu is not FDA approved and has no established medical use.
Who Should Avoid AHK-Cu?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Known copper or ingredient sensitivity
Copper contact allergy is uncommon but documented
Wilson disease or copper-metabolism disorders
Copper load is unstudied
Broken or inflamed skin
No tolerability data for compromised skin
Long-term or repeated use
No safety data
AHK-Cu Side Effects, Risks and Safety
Local irritation or rednessReported for topical copper peptides generally
Important limitation: No AHK-Cu-specific incidence data.
Allergic contact dermatitisUncommon
Important limitation: A 2014 review reported positive copper patch-test reactions in roughly 3.8% of tested subjects.
Microneedling-related effectsTransient redness, pinpoint bleeding
Important limitation: A risk of the technique, independent of the peptide.
Copper accumulationTheoretical
Important limitation: No human copper-balance study of topical AHK-Cu.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
AHK-Cu Timeline and Monitoring
Peak effect
Not established.
Cycle length
Not established.
Monitoring
No validated monitoring schedule or stopping rule exists.
AHK-Cu Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Hair growth support | Not established | In-vitro and ex-vivo dermal papilla research | No human trial of AHK-Cu |
| Skin or collagen support | Not established | Extrapolated from copper-peptide (GHK-Cu) literature | No AHK-Cu human study |
| Anti-aging claims | Not established | Marketing extrapolation | No controlled data |
AHK-Cu Storage and Handling
Unreconstituted vial
No AHK-Cu-specific stability study was identified; follow the exact product label.
Finished serum
Copper-peptide solutions are light- and oxidation-sensitive; community practice is refrigeration and small batches. No validated shelf life exists.
Cosmetic formulation
Follow the product-specific label; no universal condition is established.
Appearance
Cloudiness, discoloration, or particles do not establish safe usability.
AHK-Cu Troubleshooting
Serum changes color
Copper peptide solutions oxidize; discard rather than assume the strength on the label still applies.
Calculated concentration looks wrong
Recheck the vial quantity in milligrams and the measured carrier volume.
Conflicting percentages online
No validated human concentration exists; the 0.1–0.2% figures are DIY convention, not study results.
Skin reaction after application
Stop and seek licensed clinical review; copper contact allergy is documented though uncommon.
A scheduled application is missed
No validated missed-application procedure exists.
AHK-Cu Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| AHK-Cu | Ala-His-Lys copper tripeptide | In-vitro and ex-vivo follicle studies | Not approved |
| GHK-Cu | Gly-His-Lys copper tripeptide | Larger collagen and wound-healing literature | Not approved |
| Glow blend | GHK-Cu + BPC-157 + TB-500 vendor blend | No direct studies | Not approved |
AHK-Cu Frequently Asked Questions
Is AHK-Cu injected or applied topically?
In community use it is topical. The powder is dissolved into a serum and applied to the scalp or skin, sometimes with microneedling. The original hair research was an in-vitro and ex-vivo follicle study, not an injection protocol.
What concentration do community sources use?
Self-reported formulations commonly land around 1–2 mg/mL (roughly 0.1–0.2%) for daily scalp application. These are DIY conventions, not validated doses.
Has AHK-Cu been studied in humans?
No published human trial was identified.
Has it been studied in animals?
No published animal dosing study was identified.
Is it FDA approved?
No.
What is its half-life?
Not established.
Is AHK-Cu the same as GHK-Cu?
No. They are related copper peptides with different amino-acid sequences, and evidence does not transfer between them.
Does microneedling help it absorb?
Unknown for AHK-Cu. Microneedling studies were run with other compounds, so that rationale is borrowed rather than tested.
What does the calculator do?
It converts entered powder quantity and carrier volume into concentration math only.
Sources and Research
In-vitro / ex-vivo study
1. Pyo et al., Arch Pharm Res (2007)
AHK-Cu effective concentrations on human hair follicles and dermal papilla cells in vitro.
Open direct sourceReview
2. Pickart & Margolina, Int J Mol Sci (2018)
Copper-peptide (GHK-Cu) skin and regenerative actions; analogy context only.
Open direct sourceRandomized pilot
3. Dhurat et al., Int J Trichology (2013)
Microneedling plus minoxidil hair-count change; penetration-aid context, not an AHK-Cu study.
Open direct sourceClinical study
4. Copper-peptide microneedling for androgenetic alopecia, JAAD Int (2025)
Reported regrowth with copper-peptide microneedling; did not test AHK-Cu as a standalone topical.
Open direct sourceReview
5. Fage et al., Contact Dermatitis (2014)
Copper as a weak sensitizer; patch-test reactivity around 3.8%.
Open direct sourceVendor listing
6. AHK-Cu 50mg product listing
Vendor listing confirming vial size and price; not evidence of effect.
Open direct sourceMissing information flagged for review
- Human trial of any kind: Not established
- Animal dosing study: Not established
- Validated topical concentration and frequency: Not established
- Skin penetration and pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Compound-specific stability and shelf life: Not established
- Long-term safety: Not established
- Drug interactions: Not established